-
Survival trends for left and right sided colon cancer using population‐based SEER database: A forty‐five‐year analysis from 1975 to 2019 Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Mark B. Ulanja, Kwabena Oppong Asafo‐Agyei, Vijay Neelam, Bryce D. Beutler, Daniel Antwi‐Amoabeng, Samuel B. Governor, Ganiyu A. Rahman, Francis T. Djankpa, Reginald N. Ulanja, Grace B. Nteim, Tarig Mabrouk, Millicent Amankwah, Olatunji B. Alese
BackgroundSurvival differences between left‐sided colon cancer (LSCC) and right‐sided colon cancer (RSCC) has been previously reported with mixed results, with various study periods not accounting for other causes of mortality.PurposeWe sought to assess the trends in colon cancer cause‐ specific survival (CSS) and overall survival (OS) based on sidedness.MethodFine‐Gray competing risk and Cox models
-
Effects of resistance training on sleep quality and disorders among individuals diagnosed with cancer: A systematic review and meta‐analysis of randomized controlled trials Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Dora Maric, Salvatore Ficarra, Luca Di Bartolo, Carlo Rossi, Zoi Asimakopoulou, Apostolos Vantarakis, Ana Carbonell‐Baeza, David Jiménez‐Pavón, Beatriz Gomes, Paula Tavares, Rebecca Baxter, Susanna Pusa, Petra Thaller, Sofia Papakonstantinou, Musa Kirkar, Francesca Glorioso, Marina Galioto, Ambra Gentile, Ewan Thomas, Antonino Bianco
BackgroundSleep disorders are often complained by cancer patients and can last years after the end of therapies, leading to different negative consequences. Non‐pharmacological strategies such as exercise interventions may be considered to counteract this phenomenon. The literature supports the beneficial effects of aerobic training (AT), while evidence on resistance training (RT) is scarce. Accordingly
-
Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from Sweden Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Katarina Uttervall, Love Tätting, Konstantinos Lemonakis, Mousa Majd, Jacob Crafoord, Mikael Olsson, Ulf‐Henrik Mellqvist, Markus Hansson, Hareth Nahi
BackgroundMultiple myeloma (MM), an incurable disease characterized by frequent relapses and a need for multiple treatments, often progresses to a relapse/refractory status resistant to all available drugs and drug classes. Bispecific antibodies, specifically BCMA T‐cell engagers, have emerged as effective treatments for MM, demonstrating impressive efficacy. However, these treatments can adversely
-
PD‐1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Yasutoshi Kuboki, Takafumi Koyama, Nobuaki Matsubara, Yoichi Naito, Shunsuke Kondo, Kenichi Harano, Kan Yonemori, Kiyotaka Yoh, Yuan Gu, Tetsuya Mita, Xuejun Chen, Eiji Ueda, Noboru Yamamoto, Toshihiko Doi, Toshio Shimizu
BackgroundRetifanlimab is a humanized monoclonal antibody targeting programmed death protein‐1, and INCB001158 is an oral arginase inhibitor. This phase Ib study investigated retifanlimab, INCB001158, and their combination in Japanese patients with advanced solid tumors.MethodsPatients received retifanlimab (500 mg every 4 weeks [Q4W] i.v.) or escalating doses of INCB001158 (75 or 100 mg twice daily
-
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non‐high‐risk acute lymphoblastic leukemia treated according to the ALL‐MB 2008 protocol Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Alexander Popov, Guenter Henze, Grigory Tsaur, Oleg Budanov, Julia Roumiantseva, Mikhail Belevtsev, Tatiana Verzhbitskaya, Liudmila Movchan, Svetlana Lagoyko, Liudmila Zharikova, Yulia Olshanskaya, Tatiana Riger, Alena Valochnik, Natalia Miakova, Dmitry Litvinov, Olga Khlebnikova, Olga Streneva, Elena Stolyarova, Natalia Ponomareva, Galina Novichkova, Olga Aleinikova, Larisa Fechina, Alexander Karachunskiy
BackgroundQuantitative measurement of minimal residual disease (MRD) is the “gold standard” for estimating the response to therapy in childhood B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). Nevertheless, the speed of the MRD response differs for different cytogenetic subgroups. Here we present results of MRD measurement in children with BCP‐ALL, in terms of genetic subgroups with relation
-
Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Sandra Nuyts, Heleen Bollen, Avrahram Eisbruch, Primoz Strojan, William M. Mendenhall, Sweet Ping Ng, Alfio Ferlito
BackgroundPatients with head and neck cancer (HNC) may experience substantial anatomical changes during the course of radiotherapy treatment. The implementation of adaptive radiotherapy (ART) proves effective in managing the consequent impact on the planned dose distribution.MethodsThis narrative literature review comprehensively discusses the diverse strategies of ART in HNC and the documented dosimetric
-
Incidence and prevalence of musculoskeletal health conditions in survivors of childhood and adolescent cancers: A report from the Swiss childhood cancer survivor study Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Salome Christen, Katharina Roser, Luzius Mader, Maria Otth, Katrin Scheinemann, Grit Sommer, Claudia Kuehni, Gisela Michel
PurposeChildhood cancer and its treatment can cause damage to the musculoskeletal system. We aimed to determine the incidence and prevalence of musculoskeletal health conditions (MSHC) in survivors, and to investigate differences by cancer‐related characteristics.MethodsWe used data from the Childhood Cancer Registry and the Swiss Childhood Cancer Survivor Study, including survivors (≥5 years since
-
Survival and safety analysis of COVID‐19 vaccine in Chinese patients with non‐small cell lung cancer Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Wei Xu, Jing Zhao, Fang Luan, Zhizhao Zhang, Lei Liu, Hui Zhao, Bin Feng, Guobin Fu
BackgroundSevere acute respiratory syndrome coronavirus 2 disease (COVID‐19) has caused a worldwide challenging and threatening pandemic. We aimed to assess the safety and efficacy of the COVID‐19 vaccines in Non‐Small Cell Lung Cancer (NSCLC) patients.MethodsPatient self‐reported adverse events related to vaccines were recorded by follow‐up through a uniform questionnaire. Survival analysis was performed
-
Disparities in incidence and survival for patients with Ewing sarcoma in Florida Cancer Med. (IF 4.0) Pub Date : 2024-04-23 Aditi Dhir, Rachna Rahul, Qinran Liu, Dan Pham, Rachel Kronenfeld, Tulay Koru‐Sengul, Paulo S. Pinheiro
BackgroundEwing sarcoma (ES) is a malignant bone tumor most commonly affecting non‐Hispanic White (NHW) adolescent males, though recognition among Hispanic individuals is rising. Prior population‐based studies in the United States (US), utilizing Surveillance, Epidemiology, and End Results (SEER) have shown higher all‐cause mortality among White Hispanics, Blacks, and those of low socioeconomic status
-
Review of patient‐reported outcomes (PROs) and non‐PROs in randomized controlled trials addressing head/neck cancers Cancer Med. (IF 4.0) Pub Date : 2024-04-22 Michelle Gode, Clovis Mariano Faggion
BackgroundTo assess the frequency of patient‐reported outcomes (PROs) and non‐PROs in randomized controlled trials (RCTs) addressing head/neck cancers.MethodsWe included RCTs about interventions to treat head/neck cancers. PubMed was searched on September 16, 2022 and included studies published during three periods (2000–2002, 2010–2012, and 2020–2022). Data on types of outcomes and instruments to
-
Metabolite signature of human malignant thyroid tissue: A systematic review and meta‐analysis Cancer Med. (IF 4.0) Pub Date : 2024-04-22 S. Adeleh Razavi, Babak Khorsand, Pouya Salehipour, Mehdi Hedayati
BackgroundThyroid cancer (TC) is the predominant malignancy within the endocrine system. However, the standard method for TC diagnosis lacks the capability to identify the pathological condition of all thyroid lesions. The metabolomics approach has the potential to manage this problem by identifying differential metabolites.AimsThis study conducted a systematic review and meta‐analysis of the NMR‐based
-
Long noncoding RNA small nucleolar RNA host genes as prognostic molecular biomarkers in hepatocellular carcinoma: A meta‐analysis Cancer Med. (IF 4.0) Pub Date : 2024-04-18 Meng Huang, Zhiwen Zhao, Lihua Yang
BackgroundRecently, increasing data have suggested that the lncRNA small nucleolar RNA host genes (SNHGs) were aberrantly expressed in hepatocellular carcinoma (HCC), but the association between the prognosis of HCC and their expression remained unclear. The purpose of this meta‐analysis was to determine the prognostic significance of lncRNA SNHGs in HCC.MethodsWe systematically searched Embase, Web
-
Trends in colorectal cancer screening compliance and incidence among 60‐ to 74‐year‐olds in China Cancer Med. (IF 4.0) Pub Date : 2024-04-18 Mingqing Zhang, Yongdan Zhang, Lu Guo, Lizhong Zhao, Haoren Jing, Xiao Yang, Wen Zhang, Yong Zhang, Zhenguo Nie, Siwei Zhu, Shiwu Zhang, Xipeng Zhang
BackgroundCompliance with colonoscopy among elderly individuals participating in colorectal cancer (CRC) screening programs is unsatisfactory, despite a high detection rate of bowel‐related diseases. In this study, our aim was to analyze the impact of risk factors on the trends of compliance and detection rates in colonoscopy among high‐risk individuals aged 60–74.MethodsA retrospective study was conducted
-
-
-
Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Ruizhen Li, Xiaofen Li, Xin You, Minggang Su, Yuzhi Liu, Nengwen Ke, Dan Cao
BackgroundMore than half of neuroendocrine tumor (NET) patients will experience liver metastasis, and interventional therapy represented by transarterial embolization (TAE) is the main local treatment method. Surufatinib is recommended as a standard systemic treatment for advanced NETs. The efficacy and safety of surufatinib combined with TAE in the treatment of liver metastasis are undetermined. This
-
Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Ajami Gikandi, Susan N. Chi, Kee Kiat Yeo, Allison F. O'Neill, David S. Shulman, Steven G. DuBois, Natalie B. Collins
BackgroundImmune checkpoint inhibitors (ICI) have improved outcomes in a variety of adult cancers and are prescribed with increasing frequency across oncology. However, patterns of off‐label use of ICI in pediatrics remain unclear.MethodsThis is a single‐institution, retrospective cohort study evaluating off‐label ICI use in pediatric and young adult patients with cancer treated at our institution
-
Identifying predictors of COVID‐related delays in cancer‐specific medical care Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Breanna B. Greteman, Natalie J. Del Vecchio, Crystal J. Garcia‐Auguste, Amanda R. Kahl, Brian M. Gryzlak, Elizabeth A. Chrischilles, Mary E. Charlton, Sarah H. Nash
PurposeEvidence of the impact of the COVID‐19 pandemic on cancer prevention and control is growing, but little is known about patient‐level factors associated with delayed care. We analyzed data from a survey focused on Iowan cancer patients' COVID‐19 experiences in the early part of the pandemic.MethodsParticipants were recruited from the University of Iowa Holden Comprehensive Cancer Center's Patients
-
Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Shizhe Li, He Zhang, Ting Chen, Xiaowen Zhang, Guanning Shang
BackgroundThe proto‐oncogene ROS1 encodes an intrinsic type I membrane protein of the tyrosine kinase/insulin receptor family. ROS1 facilitates the progression of various malignancies via self‐mutations or rearrangements. Studies on ROS1‐directed tyrosine kinase inhibitors have been conducted, and some have been approved by the FDA for clinical use. However, the adverse effects and mechanisms of resistance
-
Understanding the financial cost of cancer clinical trial participation Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Courtney P. Williams, Luqin Deng, Nicole E. Caston, Kathleen Gallagher, Rebekah Angove, Maria Pisu, Andres Azuero, Rebecca Arend, Gabrielle B. Rocque
BackgroundThough financial hardship is a well‐documented adverse effect of standard‐of‐care cancer treatment, little is known about out‐of‐pocket costs and their impact on patients participating in cancer clinical trials. This study explored the financial effects of cancer clinical trial participation.MethodsThis cross‐sectional analysis used survey data collected in December 2022 and May 2023 from
-
Outcomes of the transformation of follicular lymphoma to diffuse large B‐cell lymphoma in the rituximab era: A population‐based study Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Wenshuai Zheng, Mingjuan Liu, Lixun Guan, Shenyu Wang
BackgroundHistological transformation (HT) to diffuse large B‐cell lymphoma (DLBCL) is a common complication of follicular lymphoma (FL) and is usually associated with a dismal outcome. However, the survival rate of these patients has improved over the last 20 years with the introduction of rituximab. This study aimed to access the outcome of transformation to DLBCL (t‐DLBCL) from FL in a retrospective
-
Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors Cancer Med. (IF 4.0) Pub Date : 2024-04-17 Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N. D'Alessandro‐Gabazza, Esteban C. Gabazza, Tetsu Kobayashi
BackgroundImmune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer. Although immune‐related adverse events have been reported to influence prognosis in non‐small cell lung cancer patients, few studies have investigated the prognostic value of immune‐related adverse events in small cell lung cancer patients. In this
-
Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study Cancer Med. (IF 4.0) Pub Date : 2024-04-16 Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, Byoung Chul Cho
ObjectiveKINDLE‐Korea is part of a real‐world KINDLE study that aimed to characterize the treatment patterns and clinical outcomes of patients with stage III non‐small cell lung cancer (NSCLC).Materials and MethodsThe KINDLE was an international real‐world study that explores patient and disease characteristics, treatment patterns, and survival outcomes. The KINDLE‐Korea included stage III NSCLC patients
-
Clinical laboratory characteristics and gene mutation spectrum of Ph‐negative MPN patients with atypical variants of JAK2, MPL, or CALR Cancer Med. (IF 4.0) Pub Date : 2024-04-15 Zhanlong Wang, Xin Tian, Jinyu Ma, Yuhui Zhang, Wenru Ta, Yifan Duan, Fengli Li, Hong Zhang, Long Chen, Shaobin Yang, Enbin Liu, Yani Lin, Weiping Yuan, Kun Ru, Jie Bai
-
The RNA‐binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA Cancer Med. (IF 4.0) Pub Date : 2024-04-15 Yafei Li, Shuoshuo Wang, Guoli Li, Chunyang Gao, Zihan Cui, Mingqi Cong, Jie Hu, Minghui Zhang, Xiaoming Jin, Haiying Sun, Dan Kong
-
Application of interpretable machine learning algorithms to predict distant metastasis in ovarian clear cell carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Qin‐Hua Guo, Feng‐Chun Xie, Fang‐Min Zhong, Wen Wen, Xue‐Ru Zhang, Xia‐Jing Yu, Xin‐Lu Wang, Bo Huang, Li‐Ping Li, Xiao‐Zhong Wang
BackgroundOvarian clear cell carcinoma (OCCC) represents a subtype of ovarian epithelial carcinoma (OEC) known for its limited responsiveness to chemotherapy, and the onset of distant metastasis significantly impacts patient prognoses. This study aimed to identify potential risk factors contributing to the occurrence of distant metastasis in OCCC.MethodsUtilizing the Surveillance, Epidemiology, and
-
The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Qi Wang, Yuxi Huang, Yu Zhu, Wenlong Zhang, Binfeng Wang, Xuefeng Du, Qiqiang Dai, Fabiao Zhang, Zheping Fang
-
PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Litang Huang, Shen Chen, Hui Liu, Lu Meng, Chengxing Liu, Xiaoting Wu, Yingying Wang, Shilan Luo, Hongbin Tu, Chunlei Wang, Ming Zhang, Xiaomei Gong
BackgroundNumerous studies have demonstrated that brain metastases patients may benefit from intracranial radiotherapy combined with immune checkpoint inhibitors (ICIs). However, it is unclear whether this treatment is effective for patients with small cell lung cancer brain metastases (SCLC‐BMs).MethodsWe conducted a retrospective study by analyzing medical records of patients with SCLC‐BMs from January
-
Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma Cancer Med. (IF 4.0) Pub Date : 2024-04-13 Han Zhao, Shaohang Cai, Yanhua Xiao, Muye Xia, Hongjie Chen, Zhiman Xie, Xiaoping Tang, Haolan He, Jie Peng, Juanjuan Chen
ObjectiveImmune tolerance and evasion play a critical role in virus‐driven malignancies. However, the phenotype and clinical significance of programmed cell death 1 (PD‐1) and its ligands, PD‐L1 and PD‐L2, in aggressive acquired immunodeficiency syndrome (AIDS)‐related non‐Hodgkin lymphoma (AR‐NHL) remain poorly understood, particularly in the Epstein–Barr virus (EBV)‐positive subset.MethodsWe used
-
Outcomes after fertility‐sparing surgery of early‐stage ovarian cancer: A nationwide population‐based study Cancer Med. (IF 4.0) Pub Date : 2024-04-12 Chia‐Yi Lee, Chun‐Ju Chiang, Yi‐Jou Tai, Heng‐Cheng Hsu, Yu‐Li Chen, Ying‐Cheng Chiang, Chia‐Ying Wu, Wen‐Chung Lee, Hsiao‐Lin Hwa, Wen‐Fang Cheng
-
Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Yaxiong Zhang, Zihong Chen, Yu Liu, Liang Han, Wei Jiang, Qiming Wang, Jianhua Shi, Liqin Lu, Jianying Li, Mingjun Zhang, Yan Huang, Yunpeng Yang, Xue Hou, Li Zhang, Jing Li, Wenfeng Fang, Gang Chen
BackgroundCombination of chidamide and anti‐PD‐L1 inhibitor produce synergistic anti‐tumor effect in advanced NSCLC patients resistant to anti‐PD‐1 treatment. However, the effect of chidamide plus envafolimab has not been reported.AimsThis study aimed to evaluate the efficacy of chidamide plus envafolimab in advanced NSCLC patients resistant toanti‐PD‐1 treatment.Materials and MethodsEligible advanced
-
Bayesian and deep‐learning models applied to the early detection of ovarian cancer using multiple longitudinal biomarkers Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Luis Abrego, Alexey Zaikin, Ines P. Marino, Mikhail I. Krivonosov, Ian Jacobs, Usha Menon, Aleksandra Gentry‐Maharaj, Oleg Blyuss
-
What is the relationship between the local population change and cancer incidence in patients with dyslipidemia: Evidence of the impact of local extinction in Korea Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Wonjeong Jeong, Dong‐Woo Choi, Woorim Kim, Kyu‐Tae Han
BackgroundChanges in the local population are intricately linked to healthcare infrastructure, which subsequently impacts the healthcare sector. A decreasing local population can result in lagging health infrastructure, potentially leading to adverse health outcomes as patients may be at risk of not receiving optimal care and treatment. While some studies have explored the relationship between chronic
-
Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Helmneh M. Sineshaw, Christina M. Zettler, Jennifer Prescott, Mahek Garg, Samhita Chakraborty, Eric M. Sarpong, Claire Bai, Andrew J. Belli, Laura L. Fernandes, Ching‐Kun Wang
-
Novel definition of textbook outcome in biliary system cancers and its influence on patients' survival and quality of life Cancer Med. (IF 4.0) Pub Date : 2024-04-10 Manar Mikhail Atyah, Li Xu, Zhiying Yang
BackgroundThe definition of textbook outcome in biliary system cancers is a developing concept in need of expansion and investigation of its association with survival and quality of life.MethodsIn this original research, we developed a novel “all or none” textbook outcome definition which addresses the rapid recovery of post‐surgical indexes, in addition to short‐term mortality, hospital re‐admission
-
The impact of the affordable care act and Medicaid expansion on colorectal cancer screening: Evidence from the 5th year of Medicaid expansion Cancer Med. (IF 4.0) Pub Date : 2024-04-09 Michael A. Preston, Mahmoud Manouchehri Amoli, Askar S. Chukmaitov, Alex H. Krist, Bassam Dahman
-
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID) Cancer Med. (IF 4.0) Pub Date : 2024-04-09 Hiroyuki Arai, Takashi Tsuda, Yu Sunakawa, Mototsugu Shimokawa, Kohei Akiyoshi, Shinya Tokunaga, Hirokazu Shoji, Kenji Kunieda, Masahito Kotaka, Toshihiko Matsumoto, Yusuke Nagata, Takuro Mizukami, Fumitaka Mizuki, Kathleen D. Danenberg, Narikazu Boku, Takako Eguchi Nakajima
BackgroundLong‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FOLFIRI based on early tumor shrinkage (ETS) in patients with RAS wild‐type metastatic colorectal cancer (mCRC).MethodsRadiologic assessment was performed to evaluate ETS
-
Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy Cancer Med. (IF 4.0) Pub Date : 2024-04-09 Dongchan Kim, Sheehyun Kim, Hyojin Song, Daehyeon Gwak, Suji Min, Ja Min Byun, Youngil Koh, Junshik Hong, Sung‐Soo Yoon, Hongseok Yun, Dong‐Yeop Shin
BackgroundAcute myeloid leukemia (AML) is characterized by clonal heterogeneity, leading to frequent relapses and drug resistance despite intensive clinical therapy. Although AML's clonal architecture has been addressed in many studies, practical monitoring of dynamic changes in those subclones during relapse and treatment is still understudied.MethodFifteen longitudinal bone marrow (BM) samples were
-
Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation Cancer Med. (IF 4.0) Pub Date : 2024-04-06 Alisha R. Pershad, Punam G. Thakkar, Joseph F. Goodman, Arjun Joshi, Seth M. Steinberg, Clint T. Allen, Charalampos S. Floudas
-
RSPO3 induced by Helicobacter pylori extracts promotes gastric cancer stem cell properties through the GNG7/β‐catenin signaling pathway Cancer Med. (IF 4.0) Pub Date : 2024-04-06 Xiwu Rao, Zhipeng Zhang, Yunzhou Pu, Gang Han, Hangjun Gong, Hao Hu, Qing Ji, Ningning Liu
BackgroundHelicobacter pylori (H. pylori) accounts for the majority of gastric cancer (GC) cases globally. The present study found that H. pylori promoted GC stem cell (CSC)‐like properties, therefore, the regulatory mechanism of how H. pylori promotes GC stemness was explored.MethodsSpheroid‐formation experiments were performed to explore the self‐renewal capacity of GC cells. The expression of R‐spondin
-
Artificial intelligence in lung cancer screening: Detection, classification, prediction, and prognosis Cancer Med. (IF 4.0) Pub Date : 2024-04-06 Wu Quanyang, Huang Yao, Wang Sicong, Qi Linlin, Zhang Zewei, Hou Donghui, Li Hongjia, Zhao Shijun
BackgroundThe exceptional capabilities of artificial intelligence (AI) in extracting image information and processing complex models have led to its recognition across various medical fields. With the continuous evolution of AI technologies based on deep learning, particularly the advent of convolutional neural networks (CNNs), AI presents an expanded horizon of applications in lung cancer screening
-
The inverted U‐shaped relationship between epinephrine and pancreatic ductal adenocarcinoma patients' survival with compensation of lymphocyte Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Bing‐Xue Li, Xiao‐Cen Zhu, Xia‐Xing Deng
-
Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Ryosuke Uekusa, Akira Yokoi, Eri Watanabe, Kosuke Yoshida, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Nobuhisa Yoshikawa, Kaoru Niimi, Shiro Suzuki, Hiroaki Kajiyama
BackgroundPoly (ADP‐ribose) polymerase (PARP) inhibitors have been increasingly used in the treatment of ovarian cancer, with BRCA positivity and homologous recombination deficiency (HRD) being common biomarkers used for predicting their efficacy. However, given the limitations of these biomarkers, new ones need to be explored.MethodsThis retrospective study included 181 ovarian cancer patients who
-
Household income and health‐related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Haley Newman, Yimei Li, Yuan‐Shung V. Huang, Caitlin W. Elgarten, Regina M. Myers, Jenny Ruiz, Daniel J. Zheng, Alison Barz Leahy, Catherine Aftandilian, Staci D. Arnold, Kira Bona, M. Monica Gramatges, Mallorie B. Heneghan, Kelly W. Maloney, Arunkumar J. Modi, Rajen J. Mody, Elaine Morgan, Jeffrey Rubnitz, Naomi Winick, Jennifer J. Wilkes, Alix E. Seif, Brian T. Fisher, Richard Aplenc, Kelly D. Getz
ObjectiveExamine the influence of household income on health‐related quality of life (HRQOL) among children with newly diagnosed acute myeloid leukemia (AML).DesignSecondary analysis of data prospectively collected from pediatric patients receiving treatment for AML at 14 hospitals across the United States.ExposureHousehold income was self‐reported on a demographic survey. The examined mediators included
-
Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patients Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Chih‐Cheng Chen, Ming‐Chung Kuo, Ying‐Hsuan Wang, Sung‐Nan Pei, Ming‐Lih Huang, Chiu‐Chen Chen, Cih‐En Huang, Yi‐Yang Chen, Lee‐Yung Shih
-
Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Linlin Zheng, Yaru Wang, Zhenrong Liu, Zhihao Wang, Changcheng Tao, Anke Wu, Haiyang Li, Ting Xiao, Zhuo Li, Weiqi Rong
-
Changes in rural caregivers' health behaviors while supporting someone with cancer: A qualitative study Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Elizabeth A. Johnston, Katelyn E. Collins, Jazmin N. Vicario, Chris Sibthorpe, Michael J. Ireland, Belinda C. Goodwin
-
Trends in breast, colon, pancreatic, and uterine cancers in women during the COVID‐19 pandemic in North Carolina Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Sarah J. Nyante, Allison M. Deal, Hillary M. Heiling, Kyung Su Kim, Cherie M. Kuzmiak, Benjamin C. Calhoun, Emily M. Ray
-
Comparison between next‐generation sequencing and multiplex polymerase chain reaction assays for nonsmall‐cell lung cancer molecular diagnosis Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Shuji Murakami, Kanako Shinada, Yuka Otsutsumi, Fumiko Komine, Yuan Yuan, Junko Nakamura, Seigo Katakura, Tetsuro Kondo, Terufumi Kato, Tomoyuki Yokose, Haruhiro Saito
-
A population study comparing tracheal and lung adenoid cystic carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-04 Yu Gu, Songtao Lai, Yang Wang, Juan Yang, Ping Zhou, Tianxiang Chen
BackgroundThoracic adenoid cystic carcinoma (ACC) is rare, and the differences between tracheal and lung lesions have not been fully understood.MethodsPatients were identified from a Chinese cancer center (FUSCC) (2005–2022) and the Surveillance, Epidemiology, and End Results (SEER) database (2000–2019). Incidence was calculated and trends were quantified. Clinicopathological features and overall survival
-
Developing and validating a nomogram for penile cancer survival: A comprehensive study based on SEER and Chinese data Cancer Med. (IF 4.0) Pub Date : 2024-04-03 Jiawen Luo, Jintao Hu, Yelisudan Mulati, Zhikai Wu, Cong Lai, Degeng Kong, Cheng Liu, Kewei Xu
ObjectiveThe primary aim of this study was to create a nomogram for predicting survival outcomes in penile cancer patients, utilizing data from the Surveillance, Epidemiology, and End Results (SEER) and a Chinese organization.MethodsOur study involved a cohort of 5744 patients diagnosed with penile cancer from the SEER database, spanning from 2004 to 2019. In addition, 103 patients with penile cancer
-
Metformin suppresses NFE2L1 pathway activation to inhibit gap junction beta protein expression in NSCLC Cancer Med. (IF 4.0) Pub Date : 2024-04-02 Shuo Yu, Hui Ren, Tingting Liu, Xiaoyan Han, Hui Guo, Qian Ning, Yang Li, Hong Zhou, Mingwei Chen, Tinghua Hu
ObjectiveNon‐small‐cell lung cancer (NSCLC) is a deadly form of cancer that exhibits extensive intercellular communication which contributed to chemoradiotherapy resistance. Recent evidence suggests that arrange of key proteins are involved in lung cancer progression, including gap junction proteins (GJPs).Methods and ResultsIn this study, we examined the expression patterns of GJPs in NSCLC, uncovering
-
Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus‐related hepatocellular carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-02 Liming Qin, Moqin Qiu, Qiuling Lin, Binbin Jiang, Shicheng Zhan, Xueyan Wei, Junjie Wei, Yingchun Liu, Qiuping Wen, Peiqin Chen, Yanji Jiang, Zihan Zhou, Xiumei Liang, Ji Cao, Yizhen Gong, Yuying Wei, Xiaoxia Wei, Hongping Yu
-
Analysis of related factors of CRA in lung cancer patients with different serum iron levels: A retrospective cohort study Cancer Med. (IF 4.0) Pub Date : 2024-04-02 Quan‐yao Li, Wen‐xiao Yang, Hui Liu, Jia‐lin Yao, Qin Wang, Dan Lin, Jun Shi
BackgroundSerum iron, an essential component of hemoglobin (Hb) synthesis in vivo, is a crucial parameter for evaluating the body's iron storage and metabolism capacity. Iron deficiency leads to reduced Hb synthesis in red blood cells and smaller red blood cell volume, ultimately resulting in iron‐deficiency anemia. Although serum iron cannot independently evaluate iron storage or metabolism ability
-
Correction to “Dose‐dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin‐like growth factor‐1” Cancer Med. (IF 4.0) Pub Date : 2024-04-02
Leticia M. Nogueira, Jackie A. Lavigne, Gadisetti V. R. Chandramouli, Huaitian Lui, J. Carl Barrett, Stephen D. Hursting. Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1. Cancer Med. 2012; 1:275–288. doi: 10.1002/cam4.23 The typo in the co-author name has been corrected. The corrected co-author
-
Correction to “urban relatives ameliorate survival disparities for genitourinary cancer in rural patients” Cancer Med. (IF 4.0) Pub Date : 2024-04-02
Choudry M, Dindinger-Hill K, Ambrose J, et al. Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients. Cancer Med. 2024;13:e7058. https://doi.org/10.1002/cam4.7058. The revised co-author name which is shown below has been added to the online version of the article. Trevor C. Hunt.
-
Tumor analysis of MMR genes in Lynch‐like syndrome: Challenges associated with results interpretation Cancer Med. (IF 4.0) Pub Date : 2024-04-01 Paula Rofes, Núria Dueñas, Jesús del Valle, Matilde Navarro, Judith Balmaña, Teresa Ramón y Cajal, Noemí Tuset, Carmen Castillo, Sara González, Joan Brunet, Gabriel Capellá, Conxi Lázaro, Marta Pineda
-
Characterization and impact of non‐canonical WNT signaling on outcomes of urothelial carcinoma Cancer Med. (IF 4.0) Pub Date : 2024-04-01 Margaret Meagher, Harris Krause, Andrew Elliott, Alex Farrell, Emmanuel S. Antonarakis, Bruno Bastos, Elisabeth I. Heath, Christina Jamieson, Tyler F. Stewart, Aditya Bagrodia, Chadi Nabhan, Matt Oberley, Rana R. McKay, Amirali Salmasi
BackgroundNon‐canonical WNT family (WNT5A pathway) signaling via WNT5A through ROR1 and its partner, ROR2, or Frizzled2 (FZD2) is linked to processes driving tumorigenesis and therapy resistance. We utilized a large dataset of urothelial carcinoma (UC) tumors to characterize non‐canonical WNT signaling through WNT5A, ROR1, ROR2, or FZD2 expression.MethodsNextGen Sequencing of DNA (592 genes or WES)/RNA
-
A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience Cancer Med. (IF 4.0) Pub Date : 2024-04-01 Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Silvia Mangiacavalli, Anna Maria Cafro, Stefania Girlanda, Francesca Patriarca, Claudia Minotto, Giovanni Bertoldero, Gregorio Barilà, Anna Pascarella, Albana Lico, Rossella Paolini, Nicholas Rabassi, Norbert Pescosta, Marika Porrazzo, Giovanni De Sabbata, Alessandra Pompa, Giulia Bega, Stefania Cavallin, Francesca Guidotti, Magda
IntroductionIxazomib, lenalidomide, and dexamethasone (IRd) have been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the TOURMALINE‐MM1.Objectives and MethodsWe conducted a retrospective–prospective analysis of 106 RRMM patients (pts) treated with IRd in 21 centers in Northern Italy, with the aim to evaluate the efficacy and safety of IRd in real life
-
Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta‐analysis Cancer Med. (IF 4.0) Pub Date : 2024-03-30 Shoutao Dang, Xinyu Li, Heshu Liu, Shuyang Zhang, Wei Li
BackgroundImmune checkpoint inhibitors (ICIs) are widely used in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC); however, the toxicity profiles are inconclusive.MethodsClinical trials evaluating ICIs for R/M HNSCC were searched from online databases. The characteristics of the studies and the results of incidences of any grade treatment‐related adverse events (trAEs), grade